K.N. Price

873 total citations
19 papers, 597 citations indexed

About

K.N. Price is a scholar working on Cancer Research, Genetics and Oncology. According to data from OpenAlex, K.N. Price has authored 19 papers receiving a total of 597 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Cancer Research, 11 papers in Genetics and 9 papers in Oncology. Recurrent topics in K.N. Price's work include Estrogen and related hormone effects (11 papers), Breast Cancer Treatment Studies (10 papers) and Advanced Breast Cancer Therapies (4 papers). K.N. Price is often cited by papers focused on Estrogen and related hormone effects (11 papers), Breast Cancer Treatment Studies (10 papers) and Advanced Breast Cancer Therapies (4 papers). K.N. Price collaborates with scholars based in Switzerland, United States and Italy. K.N. Price's co-authors include Michael P. Link, Beat Thürlimann, RD Gelber, Richard D. Gelber, Giuseppe Viale, David Tapper, Ernest E. Lack, Allen M. Goorin, N Jaffe and J. Robert Cassady and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Annals of Oncology.

In The Last Decade

K.N. Price

19 papers receiving 573 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
K.N. Price Switzerland	10	294	256	206	201	82	19	597
D F Hayes United States	8	464 1.6×	329 1.3×	234 1.1×	152 0.8×	92 1.1×	12	765
Fulvio Brema Italy	12	388 1.3×	136 0.5×	78 0.4×	67 0.3×	79 1.0×	36	562
L. E. Shepherd Canada	15	534 1.8×	307 1.2×	246 1.2×	184 0.9×	103 1.3×	43	800
Steve van Os United States	9	199 0.7×	138 0.5×	220 1.1×	340 1.7×	64 0.8×	15	612
H.T. Mouridsen Denmark	12	566 1.9×	273 1.1×	150 0.7×	310 1.5×	85 1.0×	33	787
A. Galid Austria	9	519 1.8×	209 0.8×	111 0.5×	167 0.8×	96 1.2×	27	748
John Frye United States	10	286 1.0×	91 0.4×	51 0.2×	172 0.9×	222 2.7×	24	754
Donald I. Twito United States	11	362 1.2×	170 0.7×	175 0.8×	233 1.2×	122 1.5×	13	603
HelenJ. Stewart United Kingdom	9	231 0.8×	334 1.3×	323 1.6×	49 0.2×	69 0.8×	19	777
M. Varini Switzerland	11	319 1.1×	201 0.8×	31 0.2×	184 0.9×	108 1.3×	18	646

Countries citing papers authored by K.N. Price

Since Specialization

Citations

This map shows the geographic impact of K.N. Price's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by K.N. Price with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites K.N. Price more than expected).

Fields of papers citing papers by K.N. Price

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by K.N. Price. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by K.N. Price. The network helps show where K.N. Price may publish in the future.

Co-authorship network of co-authors of K.N. Price

This figure shows the co-authorship network connecting the top 25 collaborators of K.N. Price. A scholar is included among the top collaborators of K.N. Price based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with K.N. Price. K.N. Price is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

19 of 19 papers shown

Regan, MM, Olivia Pagani, K.N. Price, et al.. (2017). Abstract OT3-02-03: Long-term follow-up of TEXT and SOFT trials of adjuvant endocrine therapies for premenopausal women with HR+ early breast cancer. Cancer Research. 77(4_Supplement). OT3–2. 1 indexed citations

Borgquist, Signe, Anita Giobbie‐Hurder, Thomas P. Ahern, et al.. (2016). Abstract PD1-03: Cholesterol, cholesterol lowering medication use, and breast cancer outcomes in the BIG 1-98 study. Cancer Research. 76(4_Supplement). PD1–3. 2 indexed citations

Pruneri, Giancarlo, Andrea Vingiani, Giuseppe Viale, et al.. (2016). Abstract P2-08-02: Tumor-infiltrating lymphocytes (TILs) are a powerful prognostic marker in patients with triple negative breast cancer treated by induction chemotherapy with or without oral low dose cyclophosphamide-methotrexate maintenance chemotherapy (CMM). Cancer Research. 76(4_Supplement). P2–8. 1 indexed citations

Viale, Giuseppe, MM Regan, Patrizia Dell’Orto, et al.. (2011). Which patients benefit most from adjuvant aromatase inhibitors? Results using a composite measure of prognostic risk in the BIG 1-98 randomized trial. Annals of Oncology. 22(10). 2201–2207. 65 indexed citations

Bouzyk, Mark, Kathryn P. Gray, Meredith M. Regan, et al.. (2011). ESR1 and ESR2 polymorphisms in BIG 1−98 comparing adjuvant letrozole (L) versus tamoxifen (T) or their sequence for early breast cancer.. Journal of Clinical Oncology. 29(15_suppl). 1002–1002. 1 indexed citations

Huober, Jens, Beat Thürlimann, Meredith M. Regan, et al.. (2010). Prognosis of medullary breast cancer: Analyses of 13 International Breast Cancer Study Group (IBCSG) trials.. Journal of Clinical Oncology. 28(15_suppl). 630–630. 4 indexed citations

Leyland-Jones, B, MM Regan, Mark Bouzyk, et al.. (2010). Abstract S1-8: Outcome According to CYP2D6 Genotype among Postmenopausal Women with Endocrine-Responsive Early Invasive Breast Cancer Randomized in the BIG 1-98 Trial. Cancer Research. 70(24_Supplement). S1–8. 44 indexed citations

Colleoni, Marco, Zijie Sun, Giovanni Martinelli, et al.. (2009). The effect of endocrine responsiveness on high-risk breast cancer treated with dose-intensive chemotherapy: results of International Breast Cancer Study Group Trial 15-95 after prolonged follow-up. Annals of Oncology. 20(8). 1344–1351. 11 indexed citations

Mouridsen, H.T., Anita Giobbie‐Hurder, L. Mauriac, et al.. (2009). BIG 1-98: A randomized double-blind phase III study evaluating letrozole and tamoxifen given in sequence as adjuvant endocrine therapy for postmenopausal women with receptor-positive breast cancer.. Cancer Research. 69(2_Supplement). 13–13. 30 indexed citations

10.

Giobbie‐Hurder, Anita, MM Regan, Patrizia Dell’Orto, et al.. (2008). Prognostic and predictive value of centrally reviewed Ki-67 labeling index in postmenopausal women with endocrine-responsive breast cancer: results from trial BIG 1-98 comparing adjuvant endocrine therapy with tamoxifen versus letrozole. Journal of Clinical Oncology. 26. 5569–5575. 3 indexed citations

11.

Stein, Torsten, Emilio Cosimo, Paul J. Smith, et al.. (2008). Reelin expression in breast tumours is associated with increased survival and is controlled by promoter methylation. Breast Cancer Research. 10(S2). 5 indexed citations

12.

Mauriac, L., Aparna Keshaviah, Marc Debled, et al.. (2007). Predictors of early relapse in postmenopausal women with hormone receptor-positive breast cancer in the BIG 1-98 trial. Annals of Oncology. 18(5). 859–867. 106 indexed citations

13.

Coates, Alan S., Henning T. Mouridsen, Zijie Sun, et al.. (2007). Cardiovascular adverse events during adjuvant endocrine therapy for early breast cancer using letrozole or tamoxifen: Updated safety analysis of trial BIG 1–98. Journal of Clinical Oncology. 25(18_suppl). 521–521. 4 indexed citations

14.

Crivellari, Diana, Zijie Sun, AS Coates, et al.. (2007). Aromatase inhibitors (AI) for elderly patients: Efficacy, compliance and safety according to patient age in the BIG 1–98 trial. Journal of Clinical Oncology. 25(18_suppl). 9033–9033. 5 indexed citations

15.

Thürlimann, Beat, K.N. Price, M. Castiglione, et al.. (2001). Randomized controlled trial of ovarian function suppression plus tamoxifen versus the same endocrine therapy plus chemotherapy: is chemotherapy necessary for premenopausal women with node-positive, endocrine-responsive breast cancer? First results of International Breast Cancer Study Group Trial 11–93. The Breast. 10. 130–138. 32 indexed citations

16.

Marini, Giovanni, Susan Murray, Aron Goldhirsch, et al.. (1996). The effect of adjuvant prednisone combined with CMF on patterns of relapse and occurrence of second malignancies in patients with breast cancer. Annals of Oncology. 7(3). 245–250. 17 indexed citations

17.

Gusterson, B.A., D Jadayel, M.J. O’Hare, et al.. (1994). Expression of BCL-2 in primary breast cancer and its correlation with tumour phenotype. Annals of Oncology. 5(5). 409–414. 46 indexed citations

18.

Grier, Holcombe E., Richard D. Gelber, Bruce M. Camitta, et al.. (1987). Prognostic factors in childhood acute myelogenous leukemia.. Journal of Clinical Oncology. 5(7). 1026–1032. 80 indexed citations

19.

Goorin, Allen M., Ernest E. Lack, RD Gelber, et al.. (1984). Prognostic significance of complete surgical resection of pulmonary metastases in patients with osteogenic sarcoma: analysis of 32 patients.. Journal of Clinical Oncology. 2(5). 425–431. 140 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact